To Explore the Efficacy of Sintilimab Combined with Bevacizumab in Rectal Cancer
NCT ID: NCT06808412
Last Updated: 2025-02-05
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE2
Total Enrollment
118 participants
Study Classification
INTERVENTIONAL
Study Start Date
2024-07-05
Study Completion Date
2025-06-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a prospective, exploratory clinical study. The primary endpoint of the study is to assess the pathological complete response (pCR) rate of tumors after neoadjuvant chemotherapy for rectal cancer using sintilimab combined with bevacizumab. The aim is to evaluate the efficacy and safety of sintilimab in combination with bevacizumab in the perioperative neoadjuvant chemotherapy for rectal cancer. The study includes two cohorts: Cohort A involves a retrospective collection of rectal cancer patients who previously received the XELOX regimen in the perioperative setting. Cohort B includes rectal cancer patients undergoing perioperative treatment with sintilimab and bevacizumab combined with XELOX as a neoadjuvant regimen.
Each of the trial group and historical control group requires 59 cases. The administration method for the trial group (Cohort B) is as follows:
Sintilimab: 200 mg, intravenous, Day 1, every 3 weeks. Bevacizumab: 7.5 mg/kg, intravenous, Day 1, every 3 weeks. Chemotherapy regimen: XELOX regimen.
Each of the trial group and historical control group requires 59 cases. The administration method for the trial group (Cohort B) is as follows:
Sintilimab: 200 mg, intravenous, Day 1, every 3 weeks. Bevacizumab: 7.5 mg/kg, intravenous, Day 1, every 3 weeks. Chemotherapy regimen: XELOX regimen.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Study on the Safety and Relationship of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma
NCT07127497
Pathological Complete Response
Rectal Cancer
Neoadjuvant Chemoimmunotherapy
ACTIVE_NOT_RECRUITING
PHASE2
Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer
NCT04194359
Metastatic Colorectal Cancer
RAS Mutation
Microsatellite Stable
UNKNOWN
PHASE2
SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab in First-line Treatment of mCRC
NCT05438108
Metastatic Colorectal Cancer
UNKNOWN
PHASE2
XELOX+Bevacizumab and XELIRI + Bevacizumab Alternative Regimen as First-line Treatment for Advanced Colorectal Cancer
NCT03511183
Colorectal Neoplasms
Chemotherapy
UNKNOWN
PHASE2
XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC
NCT05970302
Tislelizumab
Bevacizumab
Oxaliplatin
+5 more
RECRUITING
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Rcctal Cancer
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with rectal cancer receiving sintilimab combined with bevacizumab and XELOX as a neoadjuvan
Group Type
EXPERIMENTAL
sintilimab combined with bevacizumab and XELOX
Intervention Type
DRUG
Patients with locally advanced low rectal cancer receiving sintilimab combined with bevacizumab and XELOX as a neoadjuvant regimen during the perioperative period.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
sintilimab combined with bevacizumab and XELOX
Patients with locally advanced low rectal cancer receiving sintilimab combined with bevacizumab and XELOX as a neoadjuvant regimen during the perioperative period.
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Cohort A:
Rectal cancer patients who have previously received perioperative XELOX regimen treatment.
* Cohort B:
1.Signed written informed consent prior to any trial-related procedures;
2.Non-bedridden cases, regardless of gender, aged 18-75 years;
3.Pathologically confirmed rectal adenocarcinoma, excluding anal squamous cell carcinoma;
4.No prior antitumor treatment for rectal cancer. For those with Lynch syndrome, no antitumor treatment has been administered for the colorectal cancer related to this diagnosis;
5.Based on high-resolution MRI, classified as T1-3bN1-2 or T3aN0 or T3bN0; no involvement of the levator ani muscle; negative mesorectal fascia (MRF) status; negative extramural vascular invasion (EMVI); no cancerous nodules;
6.ECOG performance status of 0-1;
7.Expected survival time \> 3 months;
8.Adequate organ function, with subjects meeting the following laboratory criteria:
1. Absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/L without using granulocyte colony-stimulating factor in the past 14 days.
2. Platelet count ≥ 100 x 10\^9/L without transfusion in the past 14 days.
3. Hemoglobin \> 9 g/dL without transfusion or use of erythropoietin in the past 14 days;
4. Total bilirubin ≤ 1.5 × upper limit of normal (ULN); if total bilirubin \> 1.5 × ULN but direct bilirubin ≤ ULN, enrollment is also allowed;
5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN (patients with liver metastases are allowed if ALT or AST ≤ 5 × ULN);
6. Serum creatinine ≤ 1.5 × ULN and creatinine clearance (calculated by the Cockcroft-Gault formula) ≥ 60 ml/min;
7. Good coagulation function, defined as an international normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 × ULN;
8. Normal thyroid function, defined as thyroid-stimulating hormone (TSH) within normal range. If baseline TSH is outside the normal range, subjects can still be enrolled if total T3 (or FT3) and FT4 are within normal range;
9. Normal levels of cardiac enzyme profile (subjects may still be enrolled if the investigator judges the laboratory abnormality to be of no clinical significance); (optional)
9.For female subjects of childbearing potential, a urine or serum pregnancy test must be performed within 3 days prior to the first dose of the investigational drug (Day 1 of Cycle 1) with a negative result. If the urine pregnancy test result cannot be confirmed as negative, a blood pregnancy test is required. Non-childbearing potential females are defined as those who have been postmenopausal for at least one year, or have undergone surgical sterilization or hysterectomy;
10.If there is a risk of conception, all subjects (regardless of gender) must use contraception with a failure rate of less than 1% throughout the treatment period and until 120 days after the last dose of the investigational drug (or 180 days after the last dose of chemotherapy).
Rectal cancer patients who have previously received perioperative XELOX regimen treatment.
* Cohort B:
1.Signed written informed consent prior to any trial-related procedures;
2.Non-bedridden cases, regardless of gender, aged 18-75 years;
3.Pathologically confirmed rectal adenocarcinoma, excluding anal squamous cell carcinoma;
4.No prior antitumor treatment for rectal cancer. For those with Lynch syndrome, no antitumor treatment has been administered for the colorectal cancer related to this diagnosis;
5.Based on high-resolution MRI, classified as T1-3bN1-2 or T3aN0 or T3bN0; no involvement of the levator ani muscle; negative mesorectal fascia (MRF) status; negative extramural vascular invasion (EMVI); no cancerous nodules;
6.ECOG performance status of 0-1;
7.Expected survival time \> 3 months;
8.Adequate organ function, with subjects meeting the following laboratory criteria:
1. Absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/L without using granulocyte colony-stimulating factor in the past 14 days.
2. Platelet count ≥ 100 x 10\^9/L without transfusion in the past 14 days.
3. Hemoglobin \> 9 g/dL without transfusion or use of erythropoietin in the past 14 days;
4. Total bilirubin ≤ 1.5 × upper limit of normal (ULN); if total bilirubin \> 1.5 × ULN but direct bilirubin ≤ ULN, enrollment is also allowed;
5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN (patients with liver metastases are allowed if ALT or AST ≤ 5 × ULN);
6. Serum creatinine ≤ 1.5 × ULN and creatinine clearance (calculated by the Cockcroft-Gault formula) ≥ 60 ml/min;
7. Good coagulation function, defined as an international normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 × ULN;
8. Normal thyroid function, defined as thyroid-stimulating hormone (TSH) within normal range. If baseline TSH is outside the normal range, subjects can still be enrolled if total T3 (or FT3) and FT4 are within normal range;
9. Normal levels of cardiac enzyme profile (subjects may still be enrolled if the investigator judges the laboratory abnormality to be of no clinical significance); (optional)
9.For female subjects of childbearing potential, a urine or serum pregnancy test must be performed within 3 days prior to the first dose of the investigational drug (Day 1 of Cycle 1) with a negative result. If the urine pregnancy test result cannot be confirmed as negative, a blood pregnancy test is required. Non-childbearing potential females are defined as those who have been postmenopausal for at least one year, or have undergone surgical sterilization or hysterectomy;
10.If there is a risk of conception, all subjects (regardless of gender) must use contraception with a failure rate of less than 1% throughout the treatment period and until 120 days after the last dose of the investigational drug (or 180 days after the last dose of chemotherapy).
Exclusion Criteria
\- 1. Diagnosed with malignant diseases other than rectal cancer within 5 years prior to the first administration (excluding cured basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or completely excised in situ carcinoma); 2.Currently participating in an interventional clinical study treatment, or received other investigational drugs or used investigational devices within 4 weeks prior to the first administration; 3.Previously received the following therapies: anti-PD-1, anti-PD-L1, or anti-PD-L2 drugs, or drugs targeting another stimulus or co-inhibitory T cell receptors (including but not limited to CTLA-4, OX-40, CD137, etc.); 4.Received traditional Chinese medicine or immunomodulatory drugs with anti-tumor indications (including thymosin, interferon, interleukin, except for local use to control pleural effusion) within 2 weeks prior to the first administration.
5.Experienced active autoimmune diseases requiring systemic treatment (e.g., use of disease-modifying drugs, glucocorticoids, or immunosuppressants) within 2 years prior to the first administration. Alternative therapies (e.g., thyroid hormone, insulin, or physiological glucocorticoids for adrenal or pituitary insufficiency) are not considered systemic treatment;
6.Receiving systemic glucocorticoid treatment within 7 days prior to the first administration of the study (excluding nasal, inhaled, or other forms of local glucocorticoids) or any other form of immunosuppressive therapy;
Note: Physiological doses of glucocorticoids (≤10 mg/day of prednisone or equivalent) are allowed;
7.Presence of clinically uncontrollable abdominal effusion (patients who do not require drainage of effusion or who have not shown significant increase in effusion after stopping drainage for 3 days may be included);
8.Known history of allogeneic organ transplantation (except for corneal transplantation) or allogeneic hematopoietic stem cell transplantation;
9.Known allergy to the study drugs sintilimab, bevacizumab, or any active ingredients or excipients related to these investigational drugs;
10.Presence of multiple factors affecting oral medication (e.g., inability to swallow, post-gastrointestinal resection, chronic diarrhea, and bowel obstruction);
11.Not fully recovered from any toxicity and/or complications arising from any intervention prior to the start of treatment (i.e., ≤ grade 1 or return to baseline, excluding fatigue or hair loss);
12.Known history of human immunodeficiency virus (HIV) infection (i.e., positive for HIV 1/2 antibodies);
13.Untreated active hepatitis B (defined as HBsAg positive with HBV-DNA copies exceeding the upper limit of normal for the testing laboratory at the study site);
Note: Hepatitis B subjects meeting the following criteria may also be included:
HBV viral load \<1000 copies/ml (200 IU/ml) prior to the first administration; subjects should receive anti-HBV treatment throughout the study drug treatment period to prevent viral reactivation.
Subjects with anti-HBc (+), HBsAg (-), anti-HBs (-), and HBV viral load (-) do not need to receive prophylactic anti-HBV treatment but require close monitoring for viral reactivation.
14.Active HCV infection subjects (HCV antibody positive and HCV-RNA level above the lower limit of detection); 15.Received live vaccine within 30 days prior to the first administration (Cycle 1, Day 1); Note: Inactivated virus vaccine for seasonal influenza is allowed within 30 days prior to the first administration; however, intranasal live attenuated influenza vaccine is not permitted.
16.Pregnant or breastfeeding women; 17.Presence of any severe or uncontrolled systemic diseases, such as:
<!-- -->
1. Significant abnormalities in rhythm, conduction, or morphology on resting ECG that are severe and symptomatic, such as complete left bundle branch block, second-degree or higher heart block, ventricular arrhythmia, or atrial fibrillation;
2. Unstable angina, congestive heart failure, chronic heart failure classified as NYHA class ≥ 2;
3. History of any arterial thrombosis, embolism, or ischemia within 6 months prior to enrollment, such as myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack;
4. Poorly controlled blood pressure (systolic blood pressure \> 140 mmHg, diastolic blood pressure \> 90 mmHg);
5. History of non-infectious pneumonia requiring glucocorticoid treatment within 1 year prior to the first administration, or current clinically active interstitial lung disease;
6. Active pulmonary tuberculosis;
7. Presence of active or uncontrolled infections requiring systemic treatment; Clinically active diverticulitis, abdominal abscess, gastrointestinal obstruction;
8. Liver diseases such as cirrhosis, decompensated liver disease, acute or chronic active hepatitis;
9. Poorly controlled diabetes (fasting blood glucose (FBG) \> 10 mmol/L); Urinalysis indicating urine protein ≥ ++, confirmed by 24-hour urine protein quantification \> 1.0 g;
10. Presence of mental disorders and inability to cooperate with treatment;
11. Any history or evidence of disease that may interfere with study results, hinder subject participation throughout the study, abnormal treatment or laboratory test values, or other conditions deemed unsuitable for enrollment by the investigator due to potential risks.
5.Experienced active autoimmune diseases requiring systemic treatment (e.g., use of disease-modifying drugs, glucocorticoids, or immunosuppressants) within 2 years prior to the first administration. Alternative therapies (e.g., thyroid hormone, insulin, or physiological glucocorticoids for adrenal or pituitary insufficiency) are not considered systemic treatment;
6.Receiving systemic glucocorticoid treatment within 7 days prior to the first administration of the study (excluding nasal, inhaled, or other forms of local glucocorticoids) or any other form of immunosuppressive therapy;
Note: Physiological doses of glucocorticoids (≤10 mg/day of prednisone or equivalent) are allowed;
7.Presence of clinically uncontrollable abdominal effusion (patients who do not require drainage of effusion or who have not shown significant increase in effusion after stopping drainage for 3 days may be included);
8.Known history of allogeneic organ transplantation (except for corneal transplantation) or allogeneic hematopoietic stem cell transplantation;
9.Known allergy to the study drugs sintilimab, bevacizumab, or any active ingredients or excipients related to these investigational drugs;
10.Presence of multiple factors affecting oral medication (e.g., inability to swallow, post-gastrointestinal resection, chronic diarrhea, and bowel obstruction);
11.Not fully recovered from any toxicity and/or complications arising from any intervention prior to the start of treatment (i.e., ≤ grade 1 or return to baseline, excluding fatigue or hair loss);
12.Known history of human immunodeficiency virus (HIV) infection (i.e., positive for HIV 1/2 antibodies);
13.Untreated active hepatitis B (defined as HBsAg positive with HBV-DNA copies exceeding the upper limit of normal for the testing laboratory at the study site);
Note: Hepatitis B subjects meeting the following criteria may also be included:
HBV viral load \<1000 copies/ml (200 IU/ml) prior to the first administration; subjects should receive anti-HBV treatment throughout the study drug treatment period to prevent viral reactivation.
Subjects with anti-HBc (+), HBsAg (-), anti-HBs (-), and HBV viral load (-) do not need to receive prophylactic anti-HBV treatment but require close monitoring for viral reactivation.
14.Active HCV infection subjects (HCV antibody positive and HCV-RNA level above the lower limit of detection); 15.Received live vaccine within 30 days prior to the first administration (Cycle 1, Day 1); Note: Inactivated virus vaccine for seasonal influenza is allowed within 30 days prior to the first administration; however, intranasal live attenuated influenza vaccine is not permitted.
16.Pregnant or breastfeeding women; 17.Presence of any severe or uncontrolled systemic diseases, such as:
<!-- -->
1. Significant abnormalities in rhythm, conduction, or morphology on resting ECG that are severe and symptomatic, such as complete left bundle branch block, second-degree or higher heart block, ventricular arrhythmia, or atrial fibrillation;
2. Unstable angina, congestive heart failure, chronic heart failure classified as NYHA class ≥ 2;
3. History of any arterial thrombosis, embolism, or ischemia within 6 months prior to enrollment, such as myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack;
4. Poorly controlled blood pressure (systolic blood pressure \> 140 mmHg, diastolic blood pressure \> 90 mmHg);
5. History of non-infectious pneumonia requiring glucocorticoid treatment within 1 year prior to the first administration, or current clinically active interstitial lung disease;
6. Active pulmonary tuberculosis;
7. Presence of active or uncontrolled infections requiring systemic treatment; Clinically active diverticulitis, abdominal abscess, gastrointestinal obstruction;
8. Liver diseases such as cirrhosis, decompensated liver disease, acute or chronic active hepatitis;
9. Poorly controlled diabetes (fasting blood glucose (FBG) \> 10 mmol/L); Urinalysis indicating urine protein ≥ ++, confirmed by 24-hour urine protein quantification \> 1.0 g;
10. Presence of mental disorders and inability to cooperate with treatment;
11. Any history or evidence of disease that may interfere with study results, hinder subject participation throughout the study, abnormal treatment or laboratory test values, or other conditions deemed unsuitable for enrollment by the investigator due to potential risks.
Minimum Eligible Age
18 Years
Maximum Eligible Age
75 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
xiaohua li
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
xiaohua li
Associate Chief Physician
Responsibility Role
SPONSOR_INVESTIGATOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Xijing Hospital
Xi'an, Shaanxi, China
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
China
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Cremolini C, Antoniotti C, Rossini D, Lonardi S, Loupakis F, Pietrantonio F, Bordonaro R, Latiano TP, Tamburini E, Santini D, Passardi A, Marmorino F, Grande R, Aprile G, Zaniboni A, Murgioni S, Granetto C, Buonadonna A, Moretto R, Corallo S, Cordio S, Antonuzzo L, Tomasello G, Masi G, Ronzoni M, Di Donato S, Carlomagno C, Clavarezza M, Ritorto G, Mambrini A, Roselli M, Cupini S, Mammoliti S, Fenocchio E, Corgna E, Zagonel V, Fontanini G, Ugolini C, Boni L, Falcone A; GONO Foundation Investigators. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020 Apr;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9. Epub 2020 Mar 9.
Reference Type
BACKGROUND
Gruenberger T, Bridgewater J, Chau I, Garcia Alfonso P, Rivoire M, Mudan S, Lasserre S, Hermann F, Waterkamp D, Adam R. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol. 2015 Apr;26(4):702-708. doi: 10.1093/annonc/mdu580. Epub 2014 Dec 23.
Reference Type
BACKGROUND
Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB 3rd; Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007 Apr 20;25(12):1539-44. doi: 10.1200/JCO.2006.09.6305.
Reference Type
BACKGROUND
Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, Mazier MA, Canon JL, Georgoulias V, Peeters M, Bridgewater J, Cunningham D; First BEAT investigators. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol. 2009 Nov;20(11):1842-7. doi: 10.1093/annonc/mdp233. Epub 2009 Apr 30.
Reference Type
BACKGROUND
Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 2005 Jun 1;23(16):3706-12. doi: 10.1200/JCO.2005.00.232. Epub 2005 May 2.
Reference Type
BACKGROUND
Chen G, Jin Y, Guan WL, Zhang RX, Xiao WW, Cai PQ, Liu M, Lin JZ, Wang FL, Li C, Quan TT, Xi SY, Zhang HZ, Pan ZZ, Wang F, Xu RH. Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study. Lancet Gastroenterol Hepatol. 2023 May;8(5):422-431. doi: 10.1016/S2468-1253(22)00439-3. Epub 2023 Mar 1.
Reference Type
BACKGROUND
Wang F, Jin Y, Wang M, Luo HY, Fang WJ, Wang YN, Chen YX, Huang RJ, Guan WL, Li JB, Li YH, Wang FH, Hu XH, Zhang YQ, Qiu MZ, Liu LL, Wang ZX, Ren C, Wang DS, Zhang DS, Wang ZQ, Liao WT, Tian L, Zhao Q, Xu RH. Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial. Nat Med. 2024 Apr;30(4):1035-1043. doi: 10.1038/s41591-024-02813-1. Epub 2024 Mar 4.
Reference Type
BACKGROUND
Xu J, Jiang H, Pan Y, Gu K, Cang S, Han L, Shu Y, Li J, Zhao J, Pan H, Luo S, Qin Y, Guo Q, Bai Y, Ling Y, Yang J, Yan Z, Yang L, Tang Y, He Y, Zhang L, Liang X, Niu Z, Zhang J, Mao Y, Guo Y, Peng B, Li Z, Liu Y, Wang Y, Zhou H; ORIENT-16 Investigators. Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial. JAMA. 2023 Dec 5;330(21):2064-2074. doi: 10.1001/jama.2023.19918.
Reference Type
BACKGROUND
Molinari C, Passardi A. Why is neoadjuvant chemoradiation therapy underused for locally advanced rectal cancer? Expert Rev Gastroenterol Hepatol. 2016 Dec;10(12):1317-1319. doi: 10.1080/17474124.2016.1246182. Epub 2016 Oct 19. No abstract available.
Reference Type
BACKGROUND
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. doi: 10.3322/caac.21338. Epub 2016 Jan 25.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KY20242241-C-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
S-1 and Bevacizumab in Treating Patients With Colorectal Cancer That is Recurrent or Cannot Be Removed by Surgery
NCT00974389
UNKNOWN
PHASE2
Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM Patients
NCT04940546
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer
NCT04324476
UNKNOWN
PHASE2
A Phase I/II Study of XELOXIRI and Bevacizumab as First-line Treatment in Metastatic Colorectal Cancer
NCT04380103
UNKNOWN
PHASE1/PHASE2
Safety and Efficacy Study to Compare Capecitabine + Bevacizumab Versus Capecitabine, Concomitantly With Radiotherapy as Neoadjuvant Treatment for Patients With Localized and Resectable Rectal Cancer
NCT01043484
COMPLETED
PHASE2
Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer
NCT05171660
RECRUITING
PHASE3
Study of Neoadjuvant Chemotherapeutic Treatment (XELOX) Followed by Chemoradiotherapy (XELOX/RT) and Surgery Versus Chemoradiotherapy Followed by Surgery and Chemotherapy in Patients With High Risk Rectal Cancer
NCT00421824
COMPLETED
PHASE2
XELOX Combined With Cadonilimab Versus XELOX as Neoadjuvant Treatment for Locally Advanced, pMMR Rectal Cancer
NCT05815303
RECRUITING
PHASE2
A Small-sample, Real-world Study of Sintilimab Plus Bevacizumab/Cetuximab Plus XELOX Regimen for Conversion Therapy in Patients With Advanced Colorectal Cancer
NCT05544812
UNKNOWN
A Study of Avastin (Bevacizumab) and Oxaliplatin Plus Xeloda (Capecitabine) in Patients With Advanced Colorectal Cancer.
NCT01159171
COMPLETED
PHASE2
Serplulimab Combined with CAPEOX + Celecoxib As Neoadjuvant Treatment for Locally Advanced Rectal Cancer
NCT05731726
RECRUITING
PHASE2
Sintilimab Plus Bevacizumab and Chemotherapy in MSS/pMMR Colorectal With no Liver Metastasis
NCT06973343
NOT_YET_RECRUITING
PHASE2
Xeloda and Bevacizumab to Treat Rectal Cancer
NCT00847119
COMPLETED
PHASE2
Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer
NCT00321685
COMPLETED
PHASE2
Neoadjuvant Bevacizumab, Capecitabine and Radiation Therapy With or Without Oxaliplatin Locally Advanced Rectal Cancer
NCT00828672
COMPLETED
PHASE2
Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）
NCT07007767
NOT_YET_RECRUITING
PHASE2
Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer
NCT00416494
COMPLETED
PHASE2
Recombinant Human Endostatin in Combination With XELOX Therapy in Patient With Advanced Colorectal Cancer.
NCT03577392
UNKNOWN
PHASE2/PHASE3
Second-Line Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Who Have Received First-Line Chemotherapy and Bevacizumab
NCT00720512
TERMINATED
PHASE3
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
NCT00069095
COMPLETED
PHASE3
QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC
NCT05799820
UNKNOWN
PHASE2
Bevacizumab-containing Regimen for Metastatic Colorectal Cancer Failed to Cytotoxic Treatment
NCT02226289
UNKNOWN
PHASE2
Study of Bevacizumab Alone or Combined With Capecitabine and Oxaliplatin as Support Therapy in Metastatic Colorectal Cancer Patients
NCT00335595
COMPLETED
PHASE3
Study of Bevacizumab in Combination with Alternating XELIRI and XELOX in Metastatic Colorectal Cancer
NCT01531595
ACTIVE_NOT_RECRUITING
PHASE2